Ryan Arends, Ph.D.
In his current position, Dr. Ryan Arends is responsible for overseeing drug development and surveillance studies, publication generation, liquid handling systems, and managing high throughput screening campaigns. Dr. Arends has authored or coauthored over 20 microbiological publications in peer-reviewed journals and is fluent in computer programming.
Prior to his current position, Dr. Arends was a Research Scientist II at Vertex Pharmaceuticals, where he was an integral member of the antimicrobial discovery team that progressed multiple scaffolds from HTS screening hits to lead optimization compounds. Dr. Arends was also responsible for optimizing and performing bacterial growth inhibition assays to support medicinal chemistry efforts.
Dr. Arends is a member of American Society for Microbiology, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America as well as an ad hoc reviewer for several journals.
Dr. Arends completed his PhD and postdoctoral fellowship in microbiology at the University of Iowa.